Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin Kaiser, Matthew Jenner, Anand Lokare et al.|Journal of Clinical Oncology|2023Cited by 114
Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and DexamethasoneJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2018Cited by 8
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker TrialJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2019Cited by 4
Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven TrialJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2018Cited by 2
Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)Matthew Jenner, Martin Kaiser, Amy L. Sherborne et al.|Blood|2019Cited by 2